A PHASE III DOUBLE-BLIND RANDOMISED STUDY ASSESSING THE EFFICACY AND SAFETY OF CAPIVASERTIB + PACLITAXEL VERSUS PLACEBO + PACLITAXEL AS FIRST-LINE TREATMENT FOR PATIENTS WITH HISTOLOGICALLY CONFIRMED, LOCALLY ADVANCED (INOPERABLE) OR METASTATIC TRIPLE NEGATIVE BREAST CANCER

Registry ID

D3614C00001

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ASTRAZENECA CANADA INC

Start date

2021-08-12

Completion date

2024-10-01

Last update

2019-04-18

Conditions

• BREAST CANCER METASTATIC TRIPLE NEGATIVE

Related clinical trials

• A PHASE III, MULTISITE, RANDOMIZED, DOUBLE-BLIND TRIAL OF BNT327 IN COMBINATION WITH CHEMOTHERAPY VERSUS PLACEBO WITH CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY RECURRENT INOPERABLE OR METASTATIC TNBC DETERMINED INELIGIBLE FOR PD(L)1 THERAPY BASED ON PD-L1 NEGATIVE DISEASE
• A RANDOMIZED, OPEN-LABEL, PHASE 2/3 STUDY OF IZALONTAMAB BRENGITECAN (BMS-986507) VERSUS TREATMENT OF PHYSICIAN’S CHOICE IN PATIENTS WITH PREVIOUSLY UNTREATED, LOCALLY ADVANCED, RECURRENT INOPERABLE, OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC) OR ER-LOW, HER2-NEGATIVE BC WHO ARE INELIGIBLE FOR ANTI-PD1/PD-L1 TREATMENT
• A PHASE III, OPEN-LABEL, RANDOMISED STUDY OF DATOPOTAMAB DERUXTECAN (DATODXD) IN COMBINATION WITH DURVALUMAB COMPARED WITH INVESTIGATOR'S CHOICE OF CHEMOTHERAPY (PACLITAXEL, NAB-PACLITAXEL OR GEMCITABINE + CARBOPLATIN) IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-L1 POSITIVE LOCALLY RECURRENT INOPERABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TROPIONBREAST05).
• A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SACITUZUMAB GOVITECAN AND PEMBROLIZUMAB VERSUS TREATMENT OF PHYSICIAN¿S CHOICE AND PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED, LOCALLY ADVANCED, INOPERABLE, OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER, WHOSE TUMORS EXPRESS PD-L1
• A PHASE 3, OPEN-LABEL, RANDOMISED STUDY OF DATOPOTAMAB DERUXTECAN (DATODXD) VERSUS INVESTIGATOR¿S CHOICE OF CHEMOTHERAPY IN PATIENTS WHO ARE NOT CANDIDATES FOR PD 1/PD L1 INHIBITOR THERAPY IN FIRST-LINE LOCALLY RECURRENT INOPERABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TROPION BREAST02)
• AN OPEN-LABEL, RANDOMIZED, PHASE 2/3 STUDY OF OLAPARIB PLUS PEMBROLIZUMAB VERSUS CHEMOTHERAPY PLUS PEMBROLIZUMAB AFTER INDUCTION OF CLINICAL BENEFIT WITH FIRST-LINE CHEMOTHERAPY PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH LOCALLY RECURRENT INOPERABLE OR METASTATIC TRIPLE NEGATIVE BREAST CANCER (TNBC) (KEYLYNK-009)

View on source registry